Dalal Z. Husein

New Valley University
Al Kharijah, WAD 72511, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agents.

Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agents.

Journal: Future medicinal chemistry

Published: September 07, 2026

Thiazolidin-based dual Aurora kinase inhibitors with potent anticancer activity.

Thiazolidin-based dual Aurora kinase inhibitors with potent anticancer activity.

Journal: Future medicinal chemistry

Published: June 16, 2026

Coumarin-based dual kinase inhibitors targeting CDK6 and VEGFR-2: experimental and computational validation.

Coumarin-based dual kinase inhibitors targeting CDK6 and VEGFR-2: experimental and computational validation.

Journal: RSC advances

Published: May 30, 2026

New chromene derivatives as promising VEGFR-2 inhibitors: combined experimental, DFT, and molecular dynamics approaches.

New chromene derivatives as promising VEGFR-2 inhibitors: combined experimental, DFT, and molecular dynamics approaches.

Journal: Future medicinal chemistry

Published: May 19, 2026

Integrated design, synthesis, biological evaluation, and computational mechanistic insights of novel benzanilide derivatives as VEGFR-2 targeted anticancer agents.

Integrated design, synthesis, biological evaluation, and computational mechanistic insights of novel benzanilide derivatives as VEGFR-2 targeted anticancer agents.

Journal: RSC advances

Published: April 22, 2026

Structure-Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors With Potent Anticancer Activity.

Structure-Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors With Potent Anticancer Activity.

Journal: Drug development research

Published: February 20, 2026

Thiadiazole-Derived VEGFR-2 Inhibitors: From Design to Anticancer Evaluation.

Thiadiazole-Derived VEGFR-2 Inhibitors: From Design to Anticancer Evaluation.

Journal: Chemical biology & drug design

Published: February 03, 2026

New N-(isoxazol-3-yl)-4-(1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide derivatives as potent Aurora kinases inhibitors: Design, synthesis and anti-proliferative activity.

New N-(isoxazol-3-yl)-4-(1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide derivatives as potent Aurora kinases inhibitors: Design, synthesis and anti-proliferative activity.

Journal: Bioorganic chemistry

Published: January 28, 2026

Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis induction.

Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis induction.

Journal: Future medicinal chemistry

Published: August 29, 2025

Integrated computational and biological evaluations of newly synthesized thiadiazole-based VEGFR-2 inhibitors with targeted anti-breast cancer activity.

Integrated computational and biological evaluations of newly synthesized thiadiazole-based VEGFR-2 inhibitors with targeted anti-breast cancer activity.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: May 30, 2025

New Thiadiazole-Benzenesulfonamide Hybrids as Dual B-Raf/VEGFR-2 Inhibitors With Promising Anti-Hepatic Cancer Activity.

New Thiadiazole-Benzenesulfonamide Hybrids as Dual B-Raf/VEGFR-2 Inhibitors With Promising Anti-Hepatic Cancer Activity.

Journal: Chemical biology & drug design

Published: May 23, 2025

Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors.

Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors.

Journal: Future medicinal chemistry

Published: May 08, 2025

Showing 1-12 of 51

Last Updated: 09/26/2026